• Date: March 08, 2018

The Barcelona company ABAC Therapeutics has closed a Series A financing round worth 16 million euros. Specialised in discovering new antibiotics to combat multidrug-resistant bacteria, ABAC plans to allocate these funds to bring its anti-Acinetobacter baumanii programme to the clinical trial phase.

The aforementioned bacterium is a frequent cause of hospital infections, and it tops the list drawn up by the World Health Organisation of pathogens that urgently require new treatments.

Caixa Capital Risc was one of the participants in this round of financing, together with the Pontifax fund, the Global Health Science Fund, the Debiopharm Innovation Fund and the pharmaceutical company Ferrer.

More news

June 19, 2018

Three CaixaImpulse spin-offs will take part in the first-ever MedTex event

ADmit Therapeutics, CreatSens Health and GlyCardial Diagnostics are three of the 11 spin-offs taking part in the first edition of the MedTex acceleration programme.

June 12, 2018

Applications open for two EIT Health acceleration programmes

1 July is the deadline to submit applications for two of the acceleration programmes offered by EIT Health: MedTech Bootcamp and ValidationLab.

May 24, 2018

MIT-Spain "la Caixa" Foundation Seed Fund opens second call for proposals

The initiative aims to encourage collaboration between Spanish scientists and MIT, and is open to researchers from non-profit universities and research centres.